XOMA (NASDAQ: XOMA) announced the Phase 3 EYEGUARD-B study of gevokizumab in patients with Behçet's disease uveitis, run by its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments Trader Talk Trading Halts

Jefferies Downgrades XOMA, Ltd. (XOMA) to HoldJuly 23, 2015 7:23 AM Ladenburg Thalmann Downgrades XOMA, Ltd. (XOMA) to NeutralJuly 22, 2015 2:32 PM RBC Capital Downgrades XOMA, Ltd. (XOMA) to Sector PerformJuly 22, 2015 1:38 PM Cowen Downgrades XOMA, Ltd. (XOMA) to Market PerformJuly 22, 2015 12:57 PM It's NOT 'Game Over' for XOMA (XOMA), Wedbush Says; PT to $13July 22, 2015 12:55 PM Piper Jaffray Downgrades XOMA, Ltd. (XOMA) to NeutralJuly 22, 2015 11:11 AM XOMA (XOMA) Slammed 70% as Trading ResumesJuly 22, 2015 8:33 AM XOMA (XOMA) to Resume Trading at 8:30 AMJuly 22, 2015 8:03 AM XOMA (XOMA) halted with news pendingJuly 22, 2015 7:57 AM